Rheumatoid arthritis is a systemic
autoimmune disease mediated by T cells. Productive engagement of
T cell receptors by major histocompatibility complex-
peptide leads to proliferation, differentiation and the definition of effector functions. Altered
peptide ligands (APL) generated by amino acid substitutions in the antigenic
peptide have diverse effects on T cell response. We predicted a novel
T cell epitope from human
heat-shock protein 60, an
autoantigen involved in the pathogenesis of
rheumatoid arthritis. Three APLs were designed from this
epitope and it was demonstrated that these
peptides induce the activation of T cells through their ability to modify cell cycle phase's distribution of CD4+T cells from RA patients. Also,
IL-17, TNF-α and
IL-10 levels were determined in PBMC from these patients. Unlike the wild-type
peptide and the other two APLs, APL2 increased the
IL-10 level and suppressed
IL-17 secretion in these assays.
Therapeutic effect of this APL in
adjuvant arthritis (AA) and
collagen-induced arthritis (CIA) models was also evaluated. Clinical score, histopathology, inflammatory and regulatory
cytokine concentration were monitored in the animals. APL2 efficiently inhibited the progression of AA and CIA with a significant reduction of the clinical and histopathologic score.
Therapeutic effect of APL2 on CIA was similar to that obtained with MTX; the standard treatment for RA. This effect was associated with a decrease of TNF-α and
IL-17 levels. These results suggest that the
therapeutic effect of APL2 is mediated in part by down-regulation of inflammatory
cytokines and support the potential use of APL2 as a therapeutic drug in RA patients.